Drug Trial News

RSS

AbbVie releases Phase 3 results from all-oral OBV/PTV/r treatment for GT1b chronic HCV infection

AbbVie released top-line Phase 3 results for its investigational, all-oral, ribavirin (RBV)-free, two direct-acting antiviral treatment with ombitasvir/paritaprevir/ritonavir (OBV/PTV/r) in patients with genotype 1b (GT1b) chronic hepatitis C virus (HCV) infection in Japan.

31 Jan 2015

Nuvo Research announces topline results from WF10 Phase 2 allergic rhinitis clinical trial

Nuvo Research Inc., a specialty pharmaceutical company with a diverse portfolio of topical and immunology products, today announced the results of its 16-week, double-blind, placebo-controlled, Phase 2 clinical trial conducted in Germany to compare the safety and efficacy of WF10 and its main constituents (sodium chlorite and sodium chlorate) with saline in patients with refractory allergic rhinitis and to compare the safety and efficacy of WF10 and its main constituents.

30 Jan 2015

TxCell receives milestone payment of EUR 1 million concerning Ovasave collaboration, license agreement from Trizell

TxCell SA, a biotechnology company developing innovative, cost-effective, personalized T-cell immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, announces today the receipt of the latest milestone payment of EUR 1 million from the Ovasave collaboration option, development and license agreement from Trizell (Trizell Holding SA).

30 Jan 2015

ADDF awards grant to support initiation of AGB101 Phase 3 trial for aMCI treatment

The Alzheimer's Drug Discovery Foundation announced today a $900,000 grant to AgeneBio, a pharmaceutical company developing innovative therapies for neurologic and psychiatric diseases. The grant will support the initiation of an FDA-registered Phase 3 clinical trial of AGB101, a new therapeutic treatment for amnestic mild cognitive impairment (aMCI).

28 Jan 2015

Bpifrance awards TxCell EUR 1.7 million grant for clinical development of Ovasave

TxCell SA, a biotechnology company developing innovative, cost-effective, personalized T cell immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, today announces the receipt of EUR 1.7 million from Bpifrance.

27 Jan 2015

Genticel announces positive DSMB recommendation for ProCervix Phase 2 study in women with HPV

Genticel, a French biotechnology company and leading developer of therapeutic vaccines, announces today that the Data and Safety Monitoring Board, an independent committee of experts which monitors safety data every six months during the study, met as scheduled on January 22nd. It recommended the RHEIA-VAC study proceed without any modifications.

27 Jan 2015

Gem Pharmaceuticals enrolls initial soft tissue sarcoma patients in GPX-150 Phase 2 clinical trial

Gem Pharmaceuticals announced today that the initial soft tissue sarcoma (STS) patients have been enrolled into the Company's Phase 2 clinical trial. This open-label study will assess the efficacy and safety of Gem's lead compound, GPX-150 (an investigational medication), in approximately 30 adults as first-line therapy for advanced or metastatic disease.

23 Jan 2015

Efficacy of ebola vaccine to be assessed in large-scale clinical trial

GlaxoSmithKline (GSK) announced today that they will soon be commencing the first large-scale clinical trial to assess the efficacy of an experimental ebola vaccine.

23 Jan 2015

Alexza begins Phase 2a study of AZ-002 for ARS-related epilepsy management

Alexza Pharmaceuticals, Inc. announced today that it has initiated a Phase 2a study of AZ-002 (Staccato alprazolam), which is being developed for the management of epilepsy in patients with acute repetitive seizures (ARS).

22 Jan 2015

NCCS launches human clinical trial of new cancer vaccine

The National Cancer Centre Singapore has launched a clinical trial of a new cancer vaccine administered to human patients for the first time in the world. Cancer immunotherapy (the harnessing of the body's defence system to fight the patient's cancer, has emerged as one of the most exciting medical breakthroughs in the past two years.

22 Jan 2015

Neuroptis reports positive results from ML7 pre-clinical trial for treatment of dry eye syndrome

Neuroptis, a company specialized in the development of drugs to treat eye disorders, today announces positive results from a second animal trial of its preservative-free ML7 eye drops. ML7 is intended for use in the treatment of eye surface diseases, particularly dry eye syndrome.

22 Jan 2015

Eribulin therapy effective in women with metastatic breast cancer

An international research team, led by Dartmouth's Peter A. Kaufman, MD, published findings today in the Journal of Clinical Oncology demonstrating that, while not superior to capecitabine, eribulin is an active and well-tolerated therapy in women with metastatic breast cancer (MBC) receiving this therapy as a first, second, or third line chemotherapy regimen.

22 Jan 2015

Kinex Pharmaceuticals doses first actinic keratosis patient with KX2-391 ointment

Kinex Pharmaceuticals announced today that the first actinic keratosis patient has been dosed with KX2-391 ointment in Austin, Texas.

20 Jan 2015

FDA removes partial clinical hold on CytRx's aldoxorubicin clinical trials

CytRx Corporation, a biopharmaceutical research and development company specializing in oncology, today announced that the United States Food and Drug Administration has removed the partial clinical hold on the Company's aldoxorubicin clinical trials.

20 Jan 2015

Gedeon Richter, Actavis report positive top line results from cariprazine Phase III trial

Gedeon Richter Plc. and Actavis plc today announced positive results from a Phase III trial evaluating the efficacy and safety of cariprazine in the prevention of relapse in patients with schizophrenia.

20 Jan 2015

GenSpera reports encouraging results from mipsagargin Phase II study for HCC treatment

GenSpera Inc. today announced the encouraging results of a Phase II study of mipsagargin (G-202), an investigational agent for the treatment of hepatocellular carcinoma (HCC).

16 Jan 2015

Researchers assess the effect of IPT for children with anaemia in malaria endemic regions

Researchers from Tanzania and South Africa, who are part of the Cochrane Infectious Disease Group, hosted at LSTM, have conducted an independent review to assess the effect of intermittent preventive antimalarial treatment (IPT) for children with anaemia living in malaria endemic regions. This is a strategy of giving a treatment dose of antimalarial drugs to children at regular intervals just in case they have become infected.

15 Jan 2015

NIAID awards contracts to support early-stage human clinical trials of infectious disease treatments

The National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, has awarded contracts to three organizations to support early-stage human clinical trials of investigational infectious disease treatments. The new awards for the Phase I Clinical Trial Units for Therapeutics increases the number of funded organizations under the program from two to three, expanding capacity for conducting early safety testing of novel investigational drugs.

15 Jan 2015

CAR T-cell therapy enters into Phase I clinical trial

Cancer fighting chimeric antigen receptor (CAR) T cells, developed in the Sentman laboratory of Dartmouth's Norris Cotton Cancer Center, are taking the next step into a Phase I clinical trial beginning early in 2015.

15 Jan 2015

PharmaMar to begin PM1183 Phase III trial in combination with doxorubicin in SCLC

Zeltia announces today that its pharmaceutical division PharmaMar will start a Phase III trial with PM1183 in combination with doxorubicin against topotecan in SCLC, given the activity observed in an interim analysis of an ongoing Phase Ib trial. The results of this study will be presented at a prominent international cancer meeting this year, which will be soon announced.

14 Jan 2015

Drug Trial News

AbbVie releases Phase 3 results from all-oral OBV/PTV/r treatment for GT1b chronic HCV infection

Nuvo Research announces topline results from WF10 Phase 2 allergic rhinitis clinical trial

TxCell receives milestone payment of EUR 1 million concerning Ovasave collaboration, license agreement from Trizell

ADDF awards grant to support initiation of AGB101 Phase 3 trial for aMCI treatment

Bpifrance awards TxCell EUR 1.7 million grant for clinical development of Ovasave

Genticel announces positive DSMB recommendation for ProCervix Phase 2 study in women with HPV

Gem Pharmaceuticals enrolls initial soft tissue sarcoma patients in GPX-150 Phase 2 clinical trial

Efficacy of ebola vaccine to be assessed in large-scale clinical trial

Alexza begins Phase 2a study of AZ-002 for ARS-related epilepsy management

NCCS launches human clinical trial of new cancer vaccine

Neuroptis reports positive results from ML7 pre-clinical trial for treatment of dry eye syndrome

Eribulin therapy effective in women with metastatic breast cancer

Kinex Pharmaceuticals doses first actinic keratosis patient with KX2-391 ointment

FDA removes partial clinical hold on CytRx's aldoxorubicin clinical trials

Gedeon Richter, Actavis report positive top line results from cariprazine Phase III trial

GenSpera reports encouraging results from mipsagargin Phase II study for HCC treatment

Researchers assess the effect of IPT for children with anaemia in malaria endemic regions

NIAID awards contracts to support early-stage human clinical trials of infectious disease treatments

CAR T-cell therapy enters into Phase I clinical trial

PharmaMar to begin PM1183 Phase III trial in combination with doxorubicin in SCLC

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News